Detection of minimal residual disease in patients with lymphomas using the polymerase chain reaction

Important Adv Oncol. 1994:117-29.

Authors

J G Gribben¹, L M Nadler

Affiliation

¹ Harvard Medical School, Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts.

PMID: 8206485

No abstract available

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use
Bone Marrow Purging
Bone Marrow Transplantation
Chromosomes, Human, Pair 14 / ultrastructure
Chromosomes, Human, Pair 18 / ultrastructure
DNA, Neoplasm / analysis*
Gene Rearrangement, B-Lymphocyte
Genes, Immunoglobulin
Humans
Immunoglobulin Heavy Chains / genetics
Life Tables
Lymphoma, Non-Hodgkin / diagnosis
Lymphoma, Non-Hodgkin / drug therapy
Lymphoma, Non-Hodgkin / pathology*
Lymphoma, Non-Hodgkin / surgery
Neoplastic Cells, Circulating
Polymerase Chain Reaction*
Prognosis
Proto-Oncogene Proteins / genetics
Proto-Oncogene Proteins c-bcl-2
Proto-Oncogenes
Translocation, Genetic
Treatment Outcome

Substances

Antineoplastic Agents
DNA, Neoplasm
Immunoglobulin Heavy Chains
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-bcl-2